A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial

CompletedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

April 20, 2018

Study Completion Date

April 30, 2023

Conditions
Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

ALLO-ASC-DFU

"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"

Trial Locations (1)

135-720

Gangnam Severence Hospital, Seoul

All Listed Sponsors
lead

Anterogen Co., Ltd.

INDUSTRY

NCT03183934 - A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial | Biotech Hunter | Biotech Hunter